PMID- 26115728
OWN - NLM
STAT- MEDLINE
DCOM- 20160411
LR  - 20181113
IS  - 1179-1950 (Electronic)
IS  - 0012-6667 (Linking)
VI  - 75
IP  - 10
DP  - 2015 Jul
TI  - Trelagliptin: First Global Approval.
PG  - 1161-4
LID - 10.1007/s40265-015-0431-9 [doi]
AB  - Trelagliptin (Zafatek((R))) is an orally active dipeptidyl peptidase (DPP)-4 
      inhibitor developed by Takeda and approved in Japan for the treatment of type 2 
      diabetes mellitus (T2DM). Unlike other approved agents of its class, which are 
      usually administered once daily, trelagliptin can be administered once weekly. 
      Phase II development of trelagliptin was discontinued in the USA and EU, as 
      Takeda considered that the costs associated with obtaining approval in these 
      markets were prohibitive. This article summarizes the milestones in the 
      development of trelagliptin leading to this first approval for T2DM.
FAU - McKeage, Kate
AU  - McKeage K
AD  - Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand, 
      dru@adis.com.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Hypoglycemic Agents)
RN  - 56HH86ZVCT (Uracil)
RN  - Q836OWG55H (trelagliptin)
SB  - IM
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - *Drug Approval
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects/pharmacokinetics/pharmacology/therapeutic use
MH  - Japan
MH  - Uracil/adverse effects/*analogs & 
      derivatives/pharmacokinetics/pharmacology/therapeutic use
EDAT- 2015/06/28 06:00
MHDA- 2016/04/12 06:00
CRDT- 2015/06/28 06:00
PHST- 2015/06/28 06:00 [entrez]
PHST- 2015/06/28 06:00 [pubmed]
PHST- 2016/04/12 06:00 [medline]
AID - 10.1007/s40265-015-0431-9 [doi]
PST - ppublish
SO  - Drugs. 2015 Jul;75(10):1161-4. doi: 10.1007/s40265-015-0431-9.